Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine H Marshall

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Acting on Actionable Mutations in Metastatic Prostate CancerCatherine H Marshall
Current Opinion in Oncology|March 14, 2020
Therapeutic targeting of the DNA damage response in prostate cancerCatherine H Marshall, Emmanuel S Antonarakis
Blood Reviews|January 26, 2025
Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the uglyCatherine H Marshall, Emmanuel S Antonarakis, Mrinal M Patnaik
Cancer Research|August 30, 2022
Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor MalignanciesCatherine H Marshall, Lukasz P Gondek, Jun Luo, et al.
Oncoscience|July 31, 2019
CDK12 inactivation across solid tumors: an actionable genetic subtypeCatherine H Marshall, Eddie L Imada, Zhuojun Tang, et al.
The Prostate|November 16, 2021
Clinical and genomic features of SPOP-mutant prostate cancerMari Nakazawa, Mike Fang, Catherine H Marshall, et al.
Breast Cancer Research and Treatment|February 11, 2026
Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancerMadelyn F Klugman, Maya Aboumrad, Ruizhe Chen, et al.
Clinical Advances in Hematology & Oncology : H&O|June 12, 2026
Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directionsLaura M Linville, Jenna V Canzoniero, Catherine H Marshall, et al.
The Prostate|December 22, 2024
Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate CancerEtan R Aber, Michael A Carducci, Channing J Paller, et al.
BJU International|March 25, 2021
Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancerCatherine H Marshall, Jessa Tunacao, Varun Danda, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Acting on Actionable Mutations in Metastatic Prostate CancerCatherine H Marshall
Current Opinion in Oncology|March 14, 2020
Therapeutic targeting of the DNA damage response in prostate cancerCatherine H Marshall, Emmanuel S Antonarakis
Blood Reviews|January 26, 2025
Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the uglyCatherine H Marshall, Emmanuel S Antonarakis, Mrinal M Patnaik
Cancer Research|August 30, 2022
Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor MalignanciesCatherine H Marshall, Lukasz P Gondek, Jun Luo, et al.
Oncoscience|July 31, 2019
CDK12 inactivation across solid tumors: an actionable genetic subtypeCatherine H Marshall, Eddie L Imada, Zhuojun Tang, et al.
The Prostate|November 16, 2021
Clinical and genomic features of SPOP-mutant prostate cancerMari Nakazawa, Mike Fang, Catherine H Marshall, et al.
Breast Cancer Research and Treatment|February 11, 2026
Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancerMadelyn F Klugman, Maya Aboumrad, Ruizhe Chen, et al.
Clinical Advances in Hematology & Oncology : H&O|June 12, 2026
Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directionsLaura M Linville, Jenna V Canzoniero, Catherine H Marshall, et al.
The Prostate|December 22, 2024
Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate CancerEtan R Aber, Michael A Carducci, Channing J Paller, et al.
BJU International|March 25, 2021
Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancerCatherine H Marshall, Jessa Tunacao, Varun Danda, et al.
Pageof 5